<DOC>
	<DOCNO>NCT02467790</DOCNO>
	<brief_summary>To compare analysis pharmacokinetics PEX 168 patient renal insufficiency normal renal function administrate subcutaneously single dose PEX168.To evaluate dose adjustment PEX168 administer patient renal insufficiency provide scientific basis patient renal insufficiency rational drug use .</brief_summary>
	<brief_title>Polyethylene Glycol Loxenatide Pharmacokinetics Study Subjects With Normal Insufficiency Renal Function</brief_title>
	<detailed_description>This open , non-randomized , parallel-group , single-dose study evaluate pharmacokinetics PEX168 single dose administer PEX168 patient renal insufficiency normal renal function subject . The total duration subject 's participation study approximately 45 day , include 14-day Screening Period , 31-day PK sample collect Period . Center : This study conduct two site Third Xiangya hospital Center South University Shanghai Changhai Hospital.All subject receive single 200μg dos PEX168 inject subcutaneously Day 1 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Age 3165 ( inclusive ) year old , male female ; 2 . Weight : Male ≥50kg , female ≥45kg , 18≤BMI≤28 ; 3 . The CockcroftGault ( CG ) formula estimate creatinine clearance ( CLCr ) , K / DOQI definition chronic kidney disease ( CKD ) 2 patient : 60≤CLcr≤89 ml / min ; chronic kidney disease ( CKD ) 3 patient : 30≤CLcr≤59 ml / min renal insufficiency , CockcroftGault ( CG ) formula estimate creatinine clearance ( CLCr ) ≥90ml / min normal subject . 4 . In 48 hour start test end trial period , agree get rid tobacco , alcohol , caffeine , fruit juice subject ; 5 . Understand study procedure method , voluntarily participate experiment , write sign informed consent . 1 . Known suspected GLP1 class drug allergy allergy ; 2 . Before screening , receive GLP1 receptor agonist , GLP1 analog , DPPIV inhibitor similar structure drug treatment ; 3 . In addition induce renal dysfunction disease , suffer organ acute illness influence drug vivo study chronic disease ; 4. within 6 month prior screen , surgery , include impact gastric empty gastrointestinal surgery ; 5 . Screened within previous three month participate blood donation blood donation ≥400mL , participate blood donation blood transfusion within one month ; 6 . Within 3 month screen participated drug medical device trial ( include placebo ) ; 7 . Drinking , smoke addiction , drug abuse drug abuser ; 8 . In addition judge laboratory abnormality diagnosis renal dysfunction cause disease , clinically significant laboratory abnormality ( Note : Patients moderate severe anemia ( Hb &lt; 60g / L ) , severe hypertension ( SBP &gt; 160mmHg / diastolic blood pressure &gt; 100mmHg ) patient , heart rate &gt; 100bmp , ECG QTc &gt; 450ms required exclude ; 9 . ALT &gt; 1.5 time upper limit normal / aspartate transaminase &gt; 1.5 time upper limit normal / total bilirubin &gt; 1.5 time upper limit normal ; 10 . Fasting triglyceride &gt; 5.64mmol / L ( 500mg / dl ) ; 11 . Beyond normal range serum amylase , clinical significance determine investigator ; 12 . Pancreatitis , pancreatic cancer history ; 13 . Blood thyroid stimulate hormone ( TSH ) beyond normal range clinically significant judgment investigator ; 14 . The pregnancy test positive woman childbearing age , pregnant woman , breastfeed woman , within six month unwilling unable take family plan effective contraception trial male / female volunteer ; 15 . The hepatitis B surface antigen , hepatitis C antibody , HIV antibody , syphilis antibody test positive ; 16 . Researchers believe situation might lead subject complete subject study bring significant risk .</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>